Skip to main content
Caplight Logo









Strand Therapeutics

Strand Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.strandtx.com/

Last Round

Series B

Mar 17, 2026

Est. Valuation

$550M

Total Funding Raised

$266M

Company Overview

Strand Therapeutics is a biotechnology company that develops programmable, long-acting mRNA therapeutics designed to deliver precise, multi-functional treatments for cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

mRNA therapeuticsprogrammable mRNAsynthetic biologyin vivo CAR-Tsolid tumor therapytargeted cytokine therapygene therapyintratumoral therapydrug discovery platformprecision medicinebiotechnext-gen mRNAclinical stage biotechmRNA platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Strand Therapeutics Comparables

Compare Strand Therapeutics with similar companies based on industry and business-model similarity.

Strand Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kernalbio
84%
Bristol Myers Squibb
84%
Replicate Bioscience
82%

Strand Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 17, 2026
Series BAug 7, 2025
Series A ExtensionNov 28, 2022
Series AJun 23, 2021
Corporate FundingJan 11, 2021
Seed
Jun 4, 2019

Key People

Founding team and executive leadership

Jacob Becraft

Co-Founder and CEO

Founding Team

Samta Kundu

Chief Operating Officer

Executive Team

Strand Therapeutics Investors

Notable investors and investment history

Strand Therapeutics investors
InvestorRounds
Redmile GroupSeries A
Alderline GroupSeries B
ICONIQ CapitalSeries B
Camford CapitalSeries A
Playground GlobalSeries B, Series A Extension, Series A, Seed
LG Technology VenturesSeries B
ANRI株式会社Series B, Seed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Lead program STX-001 now in Phase 1 trial for solid tumors.

  • Aug 23, 2025

    Dr. Jason J. Luke appointed as new Chief Medical Officer.

Strand Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Strand Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Strand Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range125
Year Founded2017
Last FundingMar 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?